Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P23945
UPID:
FSHR_HUMAN
Alternative names:
Follitropin receptor
Alternative UPACC:
P23945; A0A0A0MSC5; A8K947; G5CBS7; G5E967; J3KQ00; Q05AH0; Q16225; Q4QRJ3; Q4ZFZ2; Q53RW2
Background:
The Follicle-stimulating hormone receptor (FSHR), also known as the Follitropin receptor, is a G protein-coupled receptor essential for reproductive biology. It binds to follitropin, activating cAMP production and downstream PI3K-AKT and ERK1/ERK2 signaling pathways, pivotal for ovarian and testicular function.
Therapeutic significance:
FSHR's involvement in diseases such as Ovarian dysgenesis 1 and Ovarian hyperstimulation syndrome highlights its critical role in reproductive health. Targeting FSHR could lead to innovative treatments for these conditions, offering hope to individuals facing infertility challenges.